NRX Pharmaceuticals Files 8-K on Financials
Ticker: NRXPW · Form: 8-K · Filed: Aug 15, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | 8-K |
| Filed Date | Aug 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
Related Tickers: NRXP
TL;DR
NRXP dropped an 8-K detailing financials as of Aug 14. Check it out.
AI Summary
NRX Pharmaceuticals, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition as of August 14, 2024. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This 8-K filing provides investors with crucial updates on NRX Pharmaceuticals' financial health and operational results, impacting investment decisions.
Risk Assessment
Risk Level: medium — 8-K filings often contain material financial information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- August 14, 2024 (date) — Earliest event reported
- August 15, 2024 (date) — Filing date
- Big Rock Partners Acquisition Corp. (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
FAQ
What specific financial information is being reported in this 8-K filing?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated August 14, 2024.
What is the Commission File Number for NRX Pharmaceuticals, Inc.?
The Commission File Number is 001-38302.
What was NRX Pharmaceuticals, Inc. formerly known as?
The company was formerly known as Big Rock Partners Acquisition Corp.
Where is NRX Pharmaceuticals, Inc. incorporated?
NRX Pharmaceuticals, Inc. is incorporated in Delaware.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2024-08-14 18:22:56
Key Financial Figures
- $0.001 — registered Common Stock, par value $0.001 per share NRXP The Nasdaq Stock Mar
Filing Documents
- nrxp20240814d_8k.htm (8-K) — 27KB
- ex_714996.htm (EX-99.1) — 49KB
- pic1.jpg (GRAPHIC) — 3KB
- pic2.jpg (GRAPHIC) — 23KB
- pic3.jpg (GRAPHIC) — 26KB
- pic4.jpg (GRAPHIC) — 13KB
- pic5.jpg (GRAPHIC) — 20KB
- 0001437749-24-026908.txt ( ) — 351KB
- nxrp-20240814.xsd (EX-101.SCH) — 4KB
- nxrp-20240814_def.xml (EX-101.DEF) — 13KB
- nxrp-20240814_lab.xml (EX-101.LAB) — 17KB
- nxrp-20240814_pre.xml (EX-101.PRE) — 13KB
- nrxp20240814d_8k_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On August 14, 2024, NRx Pharmaceuticals, Inc. (the " Company ") issued a press release announcing its financial results for the second quarter ending June 30, 2024 (the " Press Release ). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by NRx Pharmaceuticals, Inc., dated August 14, 2024.* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * This exhibit is furnished pursuant to Item 2.02 and shall not be deemed to be "filed."
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NRX PHARMACEUTICALS, INC. Date: August 14, 2024 By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Chairman of the Board of Directors